David Alleva

David Alleva is a seasoned biopharmaceutical industry professional with over 20 years of experience in drug discovery, development, and academic research.1 He currently serves as the Sr. VP of Research & Development at Evantigen, Inc., a biotech start-up focused on developing a novel vaccine delivery system.1

Professional Background

David Alleva's expertise lies in several key areas:

• Immunology and Pharmacology
• Autoimmunity (with a focus on Type 1 diabetes)
• Vaccinology
• Immunotherapeutic Discovery and Development
• Translational Research
• Assay Development

Throughout his career, he has worked on small-molecule, vaccine, and antibody therapeutic efforts for immunology and inflammation-based treatments.1

Career Highlights

• Evantigen, Inc.: Currently serving as Sr. VP of Research & Development since November 2022.1
• Akston Biosciences Corporation: Executive Director of Immunotherapeutics since September 2017.1
• IM Therapeutics: Joined as VP of Immunology in April 2021.3
• Juvenile Diabetes Research Foundation (JDRF): Led the Type 1 Diabetes immunotherapeutics investment program and portfolio from 2015 to 2017.2
• Previous roles: Held positions at Emergent BioSolutions, Hollis-Eden Pharmaceuticals, XOMA, Ltd., and Neurocrine Biosciences.2

Expertise and Contributions

David Alleva has led approximately 20 drug discovery programs across six companies, successfully bringing 10 biologic and small-molecule drugs and vaccines to clinical trials for treating or preventing autoimmune and infectious diseases.2 His major focus areas include:

• Immunotherapeutics for Type 1 diabetes
• Vaccines for COVID-19, anthrax, and HIV

Education

• Ph.D. in Immunology from Virginia Polytechnic Institute and State University
• B.S. in Biology from Indiana University
• Postdoctoral research on the genetics of Type 1 diabetes at Boston University Medical Center2

David Alleva is known for his ability to develop value propositions, therapeutic development plans, and business strategies attractive to investors. He has also demonstrated skill in securing non-dilutive financing through sources like NIH SBIR and foundation grants.